What You Need to Know About Influenza Pathways & Novel Mechanisms of Action
b'Host: John Russell, MD
\\n\\n Guest: Michael G. Ison, MD, MS
\\n\\n\\n \\n
What\\u2019s the difference between a neuraminidase inhibitor and an endonuclease inhibitor? That\\u2019s what this activity will explore, in addition to how this new endonuclease inhibitor works, if it\\u2019s for everyone, and which biologic pathways and related MOAs for antiviral agents are effective against influenza A and B.
Since the launch of the activity, the US FDA has approved a new indication for baloxavir marboxil to include the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for no more than 48 hours, who are otherwise healthy, or who are at high risk of developing flu-related complications.
'